Martin Dreyling
马丁·德雷林
MD, PhD
Professor of Medicine and Head of Lymphoma Program医学教授兼淋巴瘤项目负责人
👥Biography 个人简介
Professor Martin Dreyling is one of Europe's foremost authorities on mantle cell lymphoma (MCL) and indolent B-cell lymphomas. He chairs the European MCL Network, which has produced landmark phase III trials defining intensive induction with cytarabine-based regimens followed by autologous stem cell transplantation as standard of care for younger fit MCL patients. His work on ibrutinib and other BTK inhibitors in MCL has directly informed European regulatory approvals. Dreyling also led seminal studies on copanlisib and idelalisib in relapsed follicular lymphoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
MCL Intensive Induction and Auto-SCT
Led the European MCL Network trials establishing R-CHOP/R-DHAP alternating induction followed by autologous stem cell transplantation as the standard of care for young, fit MCL patients, significantly improving progression-free survival.
PI3K Inhibition in Follicular Lymphoma
Principal investigator for the CHRONOS-3 trial of copanlisib plus rituximab in relapsed follicular lymphoma, contributing to FDA approval of copanlisib and defining the role of PI3Kα/δ inhibition.
Ibrutinib in Relapsed MCL
Coordinated European studies of ibrutinib in relapsed/refractory MCL, establishing durable single-agent activity and defining predictors of response and resistance including TP53 and CDKN2A alterations.
Representative Works 代表性著作
Rituximab plus cytarabine-based consolidation and autologous transplantation in mantle cell lymphoma: the MCL Younger trial
Journal of Clinical Oncology (2021)
Definitive phase III evidence supporting R-CHOP/R-DHAP followed by auto-SCT as standard induction for younger MCL patients.
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3)
The Lancet Oncology (2021)
Randomized trial demonstrating PFS benefit for copanlisib combination in relapsed follicular lymphoma.
Ibrutinib in patients with relapsed or refractory mantle cell lymphoma: results from a phase II European study
Annals of Oncology (2016)
Key European phase II confirmation of ibrutinib single-agent activity in relapsed MCL.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-20 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 马丁·德雷林 的研究动态
Follow Martin Dreyling's research updates
留下邮箱，当我们发布与 Martin Dreyling（Ludwig Maximilian University of Munich, University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment